FDA approves ziftomenib for relapsed or refractory acute myeloid leukemia with a NPM1 mutation

https://prabadinews.com/

weborders@prabadincorp.com

+1 (786)-332-3938

$FDA approves ziftomenib for relapsed or refractory acute myeloid leukemia with a NPM1 mutation$

Drug Test

By AdminPrabadin - 6 hours ago

On November 13, 2025, the Food and Drug Administration approved ziftomenib (Komzifti, Kura Oncology, Inc.).

administrator

Related Articles